definiens: in a country isdefined as a Third Party ’s ( or Third Parties ’ ) sales of a generic product containing the same Collaboration Clinical Candidateas found in the Collaboration Product in question ( whether alone or in combination with other therapeutically activecompounds ), reaching a market share in such country greater than or equal to [ … * * * … ] of [COMPANY] ’s unit sales of theCollaboration Product in such country, without obtaining a license from [COMPANY] . It is understood that * * * Confidential Treatment Requested -41 - [COMPANY] shall continue to pay the Ambit royalties on Net Sales of a Collaboration Product within any given country at thefull rates otherwise applicable under this Agreement, until such time as [COMPANY] has determined and confirmed in writing toAmbit, subject to reasonable verification, that there is Substantial Generic Competition with respect to a particularCollaboration Product in such country . At such time, subject to Section 11.3.8, [COMPANY] may reduce the payment of royaltiesto Ambit in such country with respect to such Collaboration Product pursuant to this Section